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Conventional markers of kidney function that are familiar to clinicians, including the serum creatinine and blood urea nitrogen
levels, are unable to reveal genuine injury to the kidney, and their use may delay treatment. Macrophage migration inhibitory
factor (MIF) is a proinflammatory cytokine, and the predictive role and pathogenic mechanism of MIF deregulation during kidney
infections involving acute kidney injury (AKI) are not currently known. In this study, we showed that elevated urinary MIF levels
accompanied the development of AKI during kidney infection in patients with acute pyelonephritis (APN). In addition to the
MIF level, the urinary levels of interleukin (IL)-1β and kidney injury molecule (KIM)-1 were also upregulated and were positively
correlated with the levels of urinary MIF. An elevated urinary MIF level, along with elevated IL-1β and KIM-1 levels, is speculated
to be a potential biomarker for the presence of AKI in APN patients.
1. Introduction
Even minor increases in the serum creatinine level are
associated with an increased risk of inhospital morbidity and
mortality [1]. A modest decline in the glomerular filtration
rate and kidney injury should be used to diagnose kidney
damage to facilitate early detection and intervention [2, 3].
Therefore, the RIFLE (risk, injury, failure, loss, and end-
stage kidney disease) criteria replace the term “acute renal
failure” with “acute kidney injury” (AKI) [4]. However,
traditional tools, including the serum creatinine and blood
urea nitrogen (BUN) levels and urinary markers (urinary
output and urine sodium excretion) are not sufficiently
sensitive to provide an early diagnosis of AKI, and their
use may delay treatment [5, 6]. It is expected that injury
biomarkers, in addition to the functional markers, will
facilitate the early detection of renal injury.
Macrophage migration inhibitory factor (MIF) is a
potent proinflammatory cytokine that activates macrophages
and promotes the synthesis of cytokines, including tumor
necrosis factor-α, interleukin (IL)-1β, and IL-8 [7, 8].
MIF is released from an intracellular pool in response to
pathological stimuli including infection and inflammatory
activation. MIF has been shown to bind to CD74 and recruits
CD44 to form a receptor complex, resulting in the phos-
phorylation of extracellular signal-regulated kinase through
Src tyrosine kinase [8–10]. MIF also activates transcription
factors of the E-twenty-six family and upregulates Toll-like
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receptor (TLR) 4 expression and signaling to enhance the
inflammatory response [11–14]. Renal MIF is a constitutive
expression in normal kidneys and is upregulated in patients
with glomerulonephritis and renal allograft rejection. The
upregulation of MIF is associated with leukocyte infiltration,
histopathological damage, and renal dysfunction in patients
with inflammatory kidney disease [15–20]. The concen-
tration of urinary MIF is significantly correlated with the
upregulation of renal MIF expression, instead of the serum
MIF level, suggesting that the elevated level of urinary MIF is
due to MIF production in and secretion by the injured kidney
[17, 18]. The association between the urinary MIF level and
renal damage makes MIF a candidate marker for renal injury
in humans.
Acute pyelonephritis (APN) is a common infection
in which bacteria invade the renal epithelial cells and is
an important cause of renal insufficiency [21]. Although
elevated levels of urinary MIF are found in individuals with
urinary tract infections (UTIs), the upregulation of MIF in
the context of a UTI has only been found in patents with
APN [22–24]. The correlation between the urinary MIF level
and significant renal dysfunction has not yet been defined.
Therefore, the aim of this study was to investigate the ability
of aberrant urinary MIF levels to detect AKI in patients with
kidney infections.
2. Materials and Methods
2.1. Subjects and Study Design. Patient serum and urine
samples were prospectively collected between January 2010
and December 2010 in the emergency department of the
National Cheng Kung University Hospital, Tainan, Taiwan.
The diagnostic criteria for APN included fever (body temper-
ature above 38.3◦C), flank pain and/or costovertebral angle
tenderness with or without painful micturition, and pyuria.
Thirty-nine patients who were diagnosed with symptomatic
and culture-proven APN were enrolled in the study. Patients
who presented with shock, urinary tract malignancy, or
glomerulonephritis were excluded from the study. Patients
with serum creatinine levels more than 50% above baseline
were defined as having AKI according to the criteria of RIFLE
[25]. The estimated glomerular filtration rate (eGFR) was
calculated using the modification of diet in renal disease
(MDRD) formula relative to the serum creatinine level
based on age, race, and sex [26]. The blood samples for
the laboratory analysis, which included a hemogram and
analyses of the current renal function, C-reactive protein
level, and serum MIF level, were collected within 2 hours of
hospital arrival. Data including demographic information,
data on comorbidities, clinical features (including blood
pressure, oxygen saturation, respiratory rate, and conscious-
ness levels, which were necessary for calculating severity
scores), and baseline renal function were collected from the
patients’ medical records. Receiver operating curve (ROC)
analysis was used to determine the ability of the urinary
MIF level to predict AKI. To investigate the ability of MIF
to distinguish AKI from chronic kidney disease, we also
conducted a subgroup analysis including APN patients with
renal dysfunction (eGFR < 60 mL/min/1.73 m2). The severity
scores, including the Rapid Emergency Medicine Score
(REMS) and the Rapid Acute Physiology Score (RAPS), were
used as a measure of initial patient care [27, 28]. The REMS
and RAPS scoring systems are truncated versions of the Acute
Physiology and Chronic Health Evaluation (APACHEII), and
they were calculated at the time of the patient’s arrival at the
hospital. We also included patients without UTIs as control
subjects. The protocols and procedures were approved by
the institutional review board of the National Cheng Kung
University Hospital, Tainan, Taiwan.
2.2. Measurement of the Urinary Levels of MIF, IL-1β, and
Kidney Injury Molecule (KIM)-1. Serum and urine samples
were collected from APN patients and normal controls.
The levels of MIF, IL-1β, and KIM-1 were measured using
standard enzyme-linked immunosorbent assay (ELISA) kits
(R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s recommendations. All measurements were
performed in triplicate. After the reaction, the plates were
washed, and 100 μL of o-phenylenediamine substrate was
added to each well. The plates were incubated for 30 min at
room temperature, after which 50 μL of 4 N sulfuric acid was
added to each well. The plates were read at 450 nm using a
microplate reader (SpectraMax 340PC; Molecular Devices,
Inc., Sunnyvale, CA), and the data were analyzed (using
Softmax Pro software). The levels of urinary cytokines were
calculated as ratios relative to the urinary creatinine level.
2.3. Statistical Analysis. Values are expressed as the means ±
SD. Groups were compared using Student’s two-tailed
unpaired t-test or one-way analysis of variance using SPSS
17.0 (SPSS, IBM, West Grove, USA). Pearson correlation
coefficients were used to analyze the correlations between the
urinary MIF level, IL-1β level, KIM-1 level, and white blood
cell (WBC) count. A value of P < 0.05 was considered to
be statistically significant. A receiver operating characteristic
curve was used to analyze the ability to diagnose AKI based
on several parameters, and the area under the curve (AUC)
for each parameter was determined.
3. Results
3.1. There Is an Increase in Urinary MIF Levels in APN
Patients with AKI. To determine the clinical implications
of urinary MIF in patients with kidney infections, cytokine
levels and renal biochemical parameters were analyzed in
patients with APN. Thirty-nine APN patients were enrolled
in our study. Based on the RIFLE criteria [25], the patients
were divided into two groups according to the presence
of AKI. The two groups, which included 13 patients with
AKI and 26 without AKI, did not differ significantly with
respect to age, gender, comorbidities, laboratory data, disease
severity scores, or serum MIF levels except urinary MIF
levels and renal function (present BUN, creatinine, and
eGFR), as shown in Table 1. The patients with AKI had
an increase in urinary MIF compared to patients without
AKI (17.0 ± 13.2 ng/mg versus 4.2 ± 3.5 ng/mg, P = 0.004).
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Table 1: Demographic data and clinical characteristics of patients with APN.
Clinical variables






Age (yrs) 66 ± 18 73 ± 10 0.204
Male 9 (35) 4 (31) 1.000
Comorbidity
Diabetes mellitus 13 (50) 6 (46) 1.000
Hypertension 15 (58) 9 (69) 0.728
CKD (eGFR < 60 mL/min/1.73 m2) 7 (27) 6 (46) 0.290
Baseline eGFRa 79 ± 33 67 ± 46 0.322
Laboratory data
White blood cell count (k/μL) 12.7 ± 4.8 13.9 ± 8.4 0.565
Absolute neutrophil count (k/μL) 10.8 ± 4.8 11.1 ± 7.5 0.858
C-reactive protein (mg/dL) 99 ± 107 115 ± 67 0.669
Creatinine (mg/dL) 1.4 ± 1.3 3.4 ± 2.0 0.003
Blood urea nitrogen (mg/dL) 28.9 ± 29.6 68.7 ± 36.2 0.001
Current eGFRb 78 ± 40 22 ± 15 <0.001
Urine MIF (ng/mg)c 4.2 ± 3.5 17.0 ± 13.2 0.004
Serum MIF (ng/mL) 259.6 ± 240.9 279.8 ± 248.1 0.810
Gram-negative bacteriad 24 (92) 12 (92) 1.000
Severity score
REMS 7.5 ± 3.6 7.7 ± 2.8 0.893
RAPS 2.1 ± 2.0 3.2 ± 2.3 0.174
Categorical variables are expressed as a number (percentage), and continuous variables are expressed as the mean ± SD. AKI: acute kidney injury; CKD:
chronic kidney disease; eGFR: estimated glomerular filtration rate; MIF: macrophage migration inhibitory factor; REMS: rapid emergency medicine score;
RAPS: rapid acute physiology score.
aThe baseline eGFR was estimated using the MDRD equation, and the units are mL/min/1.73 m2.
bThe current eGFR was estimated by the MDRD equation using the serum creatinine level while the patient arrived at the emergency department.
cThe concentrations of MIF in the urine were measured by ELISA and were normalized based on the urinary creatinine levels. We divided the urine levels of
MIF by urine creatinine to measure the adjusted urine MIF (ng/mg).
dThe bacterial pathogens of APN were identified and proven as Gram-negative bacteria.
Table 2: Microbiological analysis of 39 patients with APN.
Invaded pathogensa





Gram-negative bacteria 24 (92) 12 (92)
E. coli 17 (65) 10 (77)
Proteus mirabilis 2 (8) 0 (0)
Klebsiella pneumoniae 1 (4) 2 (15)
Pseudomonas aeruginosa 3 (12) 0 (0)
Providencia stuartii 1 (4) 0 (0)
Gram-positive bacteria 2 (8) 1 (8)
Enterococcus species 2 (8) 0 (0)
Coagulase-negative staphylococcus 0 (0) 1 (8)
Variables are expressed as a number (percentage). AKI: acute kidney injury.
aThe bacterial pathogens of APN were identified and proven as shown later.
According to the power analysis for a two-group independent
sample t-test, a sample size of 39 subjects had a reasonable
power (0.97) to distinguish the two groups based on
urinary MIF expression. The Gram-negative bacteria are
common pathogens of UTI, including strains of Escherichia
coli, Klebsiella spp., and Proteus spp. Among them, E. coli
accounts for the 70–95% of community-acquired UTI.
The microbiological analysis of the invaded pathogens was
shown in Table 2. The majority of invaded pathogens in the
APN patients were Gram-negative bacteria (92%), and the
percentage of Gram-negative bacteria was consistent between
the two groups (92%, P = 1.000, Table 1). To adjust the
bacterial factor in altering urinary MIF expression, subgroup
analysis of patients whose pathogens were identified as
Gram-negative bacteria or E. coli was conducted in Table 3.
In APN patients, invaded pathogens were identified as
Gram-negative bacteria, and the urinary MIF was higher in
patients with AKI compared to patients without AKI (n =
36, 16.5 ng/mg ± 13.8 ng/mg versus 4.4 ng/mg ± 3.5 ng/mg,
P = 0.011). In patients whose invaded pathogens were
proven as E. coli, there was consistently an increase in urinary
MIF in APN patients with AKI compared to those without
AKI (n = 27, 15.2 ng/mg ± 11.6 ng/mg versus 4.0 ng/mg ±
3.4 ng/mg, P = 0.013). MIF has been reported to increase
and participate in the pathogenesis of diabetic nephropathy
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Table 3: Subgroup analysis of urinary MIF levels between APN patients with diabetes, renal dysfunction, or microbiological analysis.
Clinical characteristics of APN patients Number of cases Without AKI With AKI P value
Gram-negative bacteriaa 36 4.4 ± 3.5 16.5 ± 13.8 0.011
E. coli 27 4.0 ± 3.4 15.2 ± 11.6 0.013
Diabetes mellitus 19 4.1 ± 4.1 15.2 ± 8.7 0.024
Renal dysfunction on arrivalb 21 2.9 ± 2.4 17.0 ± 13.2 0.002
Urinary MIF levels (ng/mg) are expressed as the mean ± SD. AKI: acute kidney injury; eGFR: estimated glomerular filtration rate.
aThe bacterial pathogens of APN were identified and proven as Gram-negative bacteria.
bThe patients who presented with renal dysfunction (defined as eGFR < 60 mL/min/1.73 cm2) upon arrival at our emergency department were included.
[29]. Because it remains unclear whether diabetes confounds
the function of urinary MIF in detecting AKI, we analyzed
the level of urinary MIF in diabetic patients (Table 3). There
was an increase in urinary MIF levels in diabetic patients
with AKI compared to patients without AKI (n = 19, 15.2
± 8.7 ng/mg versus 4.1 ± 4.1 ng/mg, P = 0.024).
3.2. The Urinary Levels of MIF, IL-1β, and KIM-1 Are Elevated
in APN Patients with AKI. The urinary IL-1β level has been
reported to be elevated in patients with APN [30], and
urinary KIM-1 is a sensitive biomarker for AKI and is not
influenced by UTIs or chronic kidney disease [31, 32]. We
therefore evaluated the diagnostic utility of the urinary MIF,
IL-1β, and KIM-1 levels as biomarkers for AKI during kidney
infection. The levels of urinary MIF (Figure 1(a)), IL1β
(Figure 1(b)), and KIM-1 (Figure 1(c)) were significantly
higher in APN patients with AKI than in patients without
AKI or normal controls.
3.3. The Urinary Levels of MIF Were Positively Correlated
with the Urinary Levels of IL-1β and KIM-1. The Pearson
correlation coefficient was used to analyze the urinary levels
of MIF, IL-1β, and KIM-1 and the urinary WBC count. The
level of urinary MIF was positively correlated with urinary
levels of IL-1β (R2 = 0.512, P < 0.001, Figure 2(a)) and
KIM-1 (R2 = 0.319, P < 0.001, Figure 2(b)). However, no
correlation was found between the urinary level of MIF and
the urinary WBC count (R2 < 0.001, P = 0.926, Figure 2(c)).
3.4. The AUC of the Urinary Levels of MIF for Detecting
AKI among APN Patients. The ROC curve for detecting the
presence of AKI in APN patients included the urinary levels
of MIF, IL-1β, and KIM-1. The AUC for the urinary MIF
level reached 0.871 in all APN patients (Figure 3(a)). In
patient with normal renal function on arrival (defined as
eGFR ≥60 mI/min/1.73 cm2, n = 18), our result revealed
an elevated urinary MIF indicating the presence of kidney
infection compared to normal controls (4.7 ± 3.8 ng/mg
versus 0.7 ± 0.5 ng/mg, P < 0.001). Encountering patients
with abnormal renal function test, it is doubtable to
determine whether patients have AKI or preexisting chronic
kidney disease (CKD). We, therefore, analyzed the enrolled
patients who presented with renal dysfunction (defined as
eGFR< 60 mI/min/1.73 cm2 on arriving at our emergency
department, n = 21). These patients with AKI had an
increase in urinary MIF compared to patients without AKI
(17.0 ± 13.2 ng/mg versus 2.9 ± 2.4 ng/mg, P = 0.002,)
in Table 3. The AUC for the urinary MIF level in detecting
the presence of AKI reached 0.923 in patients with renal
dysfunction (Figure 3(b)). Urinary MIF helps to distinguish
the presence of AKI from pre-existing CKD.
4. Discussion
The current criteria for the diagnosis of AKI based on
elevated levels of serum creatinine or BUN are often
inadequate for the early detection of renal injury. Injury
to the renal tubules may not be sufficiently severe to cause
changes in the serum creatinine or BUN levels. Therefore,
injury biomarkers for the detection of tubular damage, used
in addition to the functional markers, may facilitate the early
recognition of renal injury. Our study revealed the elevation
of the urinary MIF level in APN patients with kidney
infection, and urinary MIF serves as an injury biomarker of
AKI in these patients.
In mice models of endotoxic shock or E. coli peritonitis,
elevated serum MIF was detected, and MIF neutralizing
antibodies protected the mice from lethal shock and sepsis
[33, 34]. Calandra et al. have reported that streptococcal
and staphylococcal exotoxin induced MIF secretion in
macrophage, and anti-MIF antibody increases survival in
mice model of exotoxin-induced shock [35]. Taken together,
these findings indicate that MIF has an important role in
bacterial infections. Several clinical studies have indicated
that septic patients with high serum MIF levels appear to
have a higher risk of mortality than patients with lower
serum MIF levels [36–38]. In our investigation, however, the
serum MIF level was not sufficient to detect the presence of
AKI. We found that the urinary MIF level is a more sensitive
indicator of kidney injury than the systemic MIF level, as
suggested by Brown et al. [17, 18]. Previous studies have
focused on the use of elevated urinary MIF levels to detect
the presence of UTIs and to distinguish kidney infections
from acute cystitis [23, 24]. In patient with normal renal
function, consistent with previous study, our study revealed
that elevated urinary MIF indicated the presence of APN.
Our investigation further demonstrated that high urinary
levels of MIF suggest the presence of AKI. In patients with
elevated serum creatinine or BUN levels, it is a clinical puzzle
to determine whether patients have AKI or pre-existing
CKD. In subgroup analysis of patients with renal dysfunction
on arrival, we revealed that the patients with AKI had an
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Figure 1: The urinary MIF level is markedly elevated in the presence of AKI in patients with kidney infections. The concentrations of MIF,
IL-1β, and KIM-1 in the urine were measured by ELISA and were normalized based on the urinary creatinine (Cr) levels. The urinary
levels of MIF (uMIF/Cr) (a), IL-1β (uIL-1β/Cr) (b), and KIM-1(uKIM-1/Cr) (c) were measured in APN patients with (n = 13) or without
(n = 26) AKI and in normal controls (n = 12). Data are the means SD. ∗∗∗P < 0.001, and ∗P < 0.05.
increase in urinary MIF compared to patients with pre-
existing CKD. MIF has been reported to be an injury marker
in kidney inflammatory disease, and consistently, our results
revealed the utility of urinary MIF in determined AKI under
infection. We, therefore, provide evidence supporting the
ability of the urinary MIF level to identify patients with AKI
and to discriminate AKI from CKD in patients with renal
dysfunction.
Our study of APN patients also revealed increased
urinary IL-1β levels in AKI patients. The urinary IL-1β
level has been previously reported as a marker for APN
[30]. IL-1β is secreted in biological fluids and thought to
be a primary initiator of the inflammatory cascade during
bacterial infection [39]. The levels of urinary IL-1β were
correlated with the levels of urinary MIF in the present
study. The regulatory role of MIF in IL-1β production has
been demonstrated in previous studies, which demonstrated
that MIF promotes inflammation through autocrine and
paracrine effects to induce the production of IL-1β by
nearby tissues or immune cells [8, 40]. Furthermore, elevated
levels of MIF in the urine have been found in individuals
with the progressive form of glomerulonephritis and those
experiencing renal allograft rejections. All of these reports
reinforce the role of MIF in renal damage [17, 18].
The urothelium contains a rich store of preformed MIF.
During cystitis, MIF is upregulated in the bladder, released
from the bladder, and detected in the urine as a potential
marker for cystitis [24, 41]. Otukesh et al. have revealed
an increase in urinary MIF in patient with APN compared
to that in patient with cystitis, suggesting renal origin,
in addition to cystic origin, for excretion of urine MIF
[23]. In human glomerulonephritis, elevated concentrations
6 Mediators of Inflammation































































Figure 2: The pairwise correlations between the urinary levels of MIF (uMIF/Cr) and the urinary level of IL-1β (uIL-1β/Cr), the urinary
level of KIM-1 (uKIM-1/Cr) and the urinary WBC (uWBC) count. Pearson correlation coefficients were used to analyze the correlation
between two variables. Each circle represents a single individual, and lines represent linear approximations.
of urinary MIF reflect the severity of renal injury and
AKI. A significant correlation of urinary MIF and renal
MIF implicates a renal origin for the excreted urine MIF
during AKI [17]. Based on the study mentioned earlier, our
investigation confirmed the applicability of urinary MIF in
detecting APN-related AKI. The stepwise increase in urinary
MIF may originate from both bladder and kidney, reflecting
the extent of bacterial invasion.
The urinary levels of MIF were correlated with the levels
of KIM-1 but not with the urinary WBC count. KIM-1 is
highly and specifically overexpressed by the proximal tubular
cells under conditions of nephrotoxic AKI and is, therefore,
a sensitive urinary biomarker to detect renal tubular injury
[42, 43]. MIF is constitutively expressed in renal tubules
in normal kidneys and released and then performs its
biological function related to renal inflammatory disease
[8]. The positive correlation between the urinary levels of
MIF and KIM-1 suggests that renal tubules are one of the
origins of urinary MIF. Renal tubular cells expressing TLRs
contribute to the activation of the inflammatory response
during ischemia-reperfusion injury in rat kidneys [44, 45].
TLR4 on renal epithelial cells activates the immune response
and participates in the renal clearance of uropathogenic E.
coli [46]. Additionally, our previous studies and those of
others have shown that inhibition of MIF suppresses TLR4-
induced inflammatory cytokine production via alternations
in ERK, p38 mitogen-activated protein kinase, and NK-κB
activation [13, 14]. The relationship between increased MIF
levels in patients with UTI-related renal inflammation and
TLR4 is, therefore, speculative.
In summary, we found that the urinary MIF level is sig-
nificantly elevated in AKI patients during kidney infection.
The elevated level of MIF was significantly correlated with
the urinary IL-1β and KIM-1 levels, which are indicative
of injury to the renal tubules. These findings suggest
that urinary MIF is a potential biomarker and that the






































Figure 3: Urinary levels of MIF detected the presence of AKI in APN patients. The receiver operating characteristic curves for the laboratory
parameters for the detection of AKI in all APN patients (n = 39) (a) or in the subgroup with renal dysfunction (eGFR < 60 ml/min/1.73 cm2,
n = 21) (b). The AUCs of the urinary MIF, IL-1β, and KIM-1 levels, which were normalized based on the urinary creatinine (Cr) levels, are
shown.
measurement of the urinary MIF level may serve as a useful
tool for recognizing nephrotoxicity in APN patients.
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